PROLONGED SURVIVAL IN CHRONIC MYELOGENOUS LEUKEMIA AFTER CYTOGENETIC RESPONSE TO INTERFERON-ALPHA THERAPY

被引:417
作者
KANTARJIAN, HM
SMITH, TL
OBRIEN, S
BERAN, M
PIERCE, S
TALPAZ, M
ROBERTSON, L
KOLLER, C
ESTEY, E
KEATING, MJ
机构
[1] M.D. Anderson Cancer Center, Houston, TX
[2] Department of Hematology, Box 61, M.D. Anderson Cancer Center, Houston, TX 77030
关键词
LEUKEMIA; MYELOID; CHRONIC; INTERFERON-ALPHA; CYTOGENETICS; BASOPHILS; SPLENOMEGALY;
D O I
10.7326/0003-4819-122-4-199502150-00003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine whether a cytogenetic response after interferon-alpha therapy in patients with chronic myelogenous leukemia is independently associated with improved survival. Design: Retrospective analysis. Patients: 274 patients with a diagnosis of Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase who were treated with interferon-alpha-based programs between 1982 and 1990. Intervention: Therapy with daily subcutaneous interferon-alpha given at 5 x 10(6) U/m(2) body surface area (highest dose schedule allowed on studies) or the maximally tolerated lower-dose schedule. Results: Overall, 219 (80%) patients achieved a complete hematologic response and 104 (38%) achieved a major cytogenetic response (<35% Philadelphia chromosome-positive cells). Estimated median survival was 89 months. Several pretreatment factors were associated with failure to achieve a major cytogenetic response and with worse survival. The existing prognostic models were generally predictive of which patients were likely to achieve a major cytogenetic response (P less than or equal to 0.01) and of survival outcomes (P less than or equal to 0.01). Multivariate analysis identified bone marrow basophilia (P < 0.01) and splenomegaly (P < 0.01) as independent poor prognostic factors for survival. Achievement of a major cytogenetic response, entered as a time-dependent variable while accounting for the other independent factors, was associated with improved survival (P < 0.001). Comparison of survival (dated from 12 months into therapy) with cytogenetic response at 12 months showed that a cytogenetic response was associated with longer survival (P < 0.001). Conclusion: Achieving a cytogenetic response with interferon-alpha therapy in patients with chronic myelogenous leukemia was independently associated with improved survival when tested as a time-dependent variable in a multivariate analysis, and this association was confirmed by landmark analysis at 12 months.
引用
收藏
页码:254 / 261
页数:8
相关论文
共 21 条
  • [1] ALIMENA G, 1988, BLOOD, V72, P642
  • [2] ANALYSIS OF SURVIVAL BY TUMOR RESPONSE
    ANDERSON, JR
    CAIN, KC
    GELBER, RD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) : 710 - 719
  • [3] COX DR, 1972, J R STAT SOC B, V34, P187
  • [4] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME
    DALEY, GQ
    VANETTEN, RA
    BALTIMORE, D
    [J]. SCIENCE, 1990, 247 (4944) : 824 - 830
  • [5] GOLDMAN JM, 1993, BLOOD, V82, P2235
  • [6] GOLDMAN JM, 1990, LEUKEMIA, V4, P163
  • [7] RANDOMIZED COMPARISON OF BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA - PROLONGATION OF SURVIVAL BY HYDROXYUREA
    HEHLMANN, R
    HEIMPEL, H
    HASFORD, J
    KOLB, HJ
    PRALLE, H
    HOSSFELD, DK
    QUEISSER, W
    LOFFLER, H
    HEINZE, B
    GEORGII, A
    VONWUSSOW, P
    BARTRAM, C
    GRIESSHAMMER, M
    BERGMANN, L
    ESSERS, U
    FALGE, C
    HOCHHAUS, A
    QUEISSER, U
    SICK, C
    MEYER, P
    SCHMITZ, N
    VERPOORT, K
    EIMERMACHER, H
    WALTHER, F
    WESTERHAUSEN, M
    KLEEBERG, UR
    HEILEIN, A
    KABISCH, A
    BARZ, C
    ZIMMERMANN, R
    MEURET, G
    TICHELLI, A
    BERDEL, WE
    KANZ, L
    ANGER, B
    TIGGES, FJ
    SCHMID, L
    BROCKHAUS, W
    ZANKOVICH, R
    SCHLAFER, U
    WEISSENFELS, I
    MAINZER, K
    TOBLER, A
    PERKER, M
    HOHNLOSER, J
    MESSENER, D
    THIELE, J
    BUHR, T
    ANSARI, H
    [J]. BLOOD, 1993, 82 (02) : 398 - 407
  • [8] KANTARJIAN HM, 1993, BLOOD, V82, P691
  • [9] PROPOSAL FOR A SIMPLE SYNTHESIS PROGNOSTIC STAGING SYSTEM IN CHRONIC MYELOGENOUS LEUKEMIA
    KANTARJIAN, HM
    KEATING, MJ
    SMITH, TL
    TALPAZ, M
    MCCREDIE, KB
    [J]. AMERICAN JOURNAL OF MEDICINE, 1990, 88 (01) : 1 - 8
  • [10] KANTARJIAN HM, 1985, BLOOD, V66, P1326